World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 95 9900 9288 5094 4705 687 44507

Corey J. Langer publications per year

The chart shows the history of publications by Corey J. Langer between 1991 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Corey J. Langer published across 35 years, from 1991 to 2025, averaging 22.5 papers a year. Output peaked at 94 publications in 2023. 34 of the 789 publications appeared in the last two years.

No. of publications
20 40 60 80
Bar chart. Horizontal axis: year, 1991 to 2025. Vertical axis: number of publications, 0 to 94. Peak 94 publications in 2023. 1991: 4 publications 1992: 0 publications 1993: 5 publications 1994: 1 publication 1995: 5 publications 1996: 3 publications 1997: 8 publications 1998: 3 publications 1999: 1 publication 2000: 11 publications 2001: 16 publications 2002: 11 publications 2003: 21 publications 2004: 28 publications 2005: 35 publications 2006: 31 publications 2007: 41 publications 2008: 34 publications 2009: 25 publications 2010: 28 publications 2011: 29 publications 2012: 42 publications 2013: 25 publications 2014: 21 publications 2015: 26 publications 2016: 33 publications 2017: 60 publications 2018: 33 publications 2019: 29 publications 2020: 20 publications 2021: 18 publications 2022: 14 publications 2023: 94 publications 2024: 22 publications 2025: 12 publications
1991 2025

789 publications in total across all disciplines

View publications per year as a table
Corey J. Langer: publications per year, 1991 to 2025
Year Publications
1991 4
1992 0
1993 5
1994 1
1995 5
1996 3
1997 8
1998 3
1999 1
2000 11
2001 16
2002 11
2003 21
2004 28
2005 35
2006 31
2007 41
2008 34
2009 25
2010 28
2011 29
2012 42
2013 25
2014 21
2015 26
2016 33
2017 60
2018 33
2019 29
2020 20
2021 18
2022 14
2023 94
2024 22
2025 12
Total 789
Download as CSV

Corey J. Langer publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Corey J. Langer sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 681–700 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 687 publications — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336 687
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Corey J. Langer D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Corey J. Langer sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 94–95 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 95 D-Index — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808 95
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Corey J. Langer is affiliated with the University of Pennsylvania in the United States. Their research primarily spans the field of medicine, with an emphasis on pulmonary and respiratory medicine and oncology.

Their work covers several subfields, including:

  • Pulmonary and Respiratory Medicine
  • Oncology
  • Cancer Research
  • Molecular Biology
  • Immunology

Corey J. Langer focuses on multiple research topics, such as:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Diagnosis and Treatment
  • Lung Cancer Research Studies
  • Cancer Genomics and Diagnostics
  • Colorectal Cancer Treatments and Studies
  • Occupational and environmental lung diseases

Frequent venues where Langer has published include:

  • Journal of Clinical Oncology
  • International Journal of Radiation Oncology*Biology*Physics
  • Clinical Lung Cancer
  • Journal of Thoracic Oncology
  • JTO Clinical and Research Reports

Corey J. Langer has collaborated extensively with several coauthors, including:

  • Roger B. Cohen
  • Charu Aggarwal
  • Melina E. Marmarelis
  • Lova Sun
  • Aditi P. Singh

Selected recent papers authored or coauthored by Langer illustrate a focus on lung cancer and immunotherapy. These include:

  • "Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial," 2020, Annals of Oncology
  • "Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407," 2021, Journal of Thoracic Oncology
  • "Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC," 2020, Journal of Thoracic Oncology
  • "Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients," 2024, Science
  • "Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer," 2020, JAMA Oncology

Best Publications

  • Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

    Joan H. Schiller;David Harrington;Chandra P. Belani;Corey Langer

  • CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

    Andy Trotti;A.Dimitrios Colevas;Ann Setser;Valerie Rusch

  • Sequential vs Concurrent Chemoradiation for Stage III Non–Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410

    Walter J. Curran;Rebecca Paulus;Corey J. Langer;Ritsuko Komaki

  • Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

    Corey J Langer;Shirish M Gadgeel;Hossein Borghaei;Vassiliki A Papadimitrakopoulou

  • Non–Small Cell Lung Cancer

    David S. Ettinger;Wallace Akerley;Gerold Bepler;Andrew Chang

  • Laryngeal Cancer in the United States: Changes in Demographics, Patterns of Care, and Survival

    Henry T. Hoffman;Kimberly Porter;Lucy H. Karnell;Jay S. Cooper

  • Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

    Nasser Hanna;Paul A. Bunn;Corey Langer;Lawrence Einhorn

  • Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial.

    Corey J. Langer;Judith Manola;Patricia Bernardo;John W. Kugler

  • Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124

    Primo N. Lara;Ronald Natale;John Crowley;Heinz Josef Lenz

  • Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

    Dong-Wan Kim;Dong-Wan Kim;Marcello Tiseo;Myung-Ju Ahn;Karen L Reckamp

  • National Cancer Database report on cancer of the head and neck: 10-year update

    Jay S. Cooper;Kim Porter;Katherine Mallin;Henry T. Hoffman

  • Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599

    Suresh S. Ramalingam;Suzanne E. Dahlberg;Corey J. Langer;Robert Gray

  • Current management of brain metastases, with a focus on systemic options

    Corey J. Langer;Minesh P. Mehta

  • Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.

    Stephen J. Bagley;Shawn Kothari;Charu Aggarwal;Joshua M. Bauml

  • Phase III comparison of sequential vs concurrent chemoradiation for pts with unresected stage III non-small cell lung cancer (NSCLC): Report of Radiation Therapy Oncology Group (RTOG) 9410

    W Curran;C Scott;C Langer;R Komaki

  • Phase II Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Results of Radiation Therapy Oncology Group Protocol 9911

    Corey J. Langer;Jonathan Harris;Eric M. Horwitz;Nicos Nicolaou

  • Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.

    Charu Aggarwal;Jeffrey C. Thompson;Taylor A. Black;Sharyn I. Katz

  • Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

    Daniel D. Karp;Luis G. Paz-Ares;Silvia Novello;Paul Haluska

  • The Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung Cancer

    Corey J. Langer;Benjamin Besse;Antonio Gualberto;Elizabeth Brambilla

  • Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

    Scott N Gettinger;Lyudmila A Bazhenova;Corey J Langer;Ravi Salgia

Frequent Co-Authors

Benjamin Movsas
Benjamin Movsas Henry Ford Health System
Scott N. Gettinger
Scott N. Gettinger Yale University
Walter J. Curran
Walter J. Curran Emory University
Mark A. Socinski
Mark A. Socinski University of North Carolina at Chapel Hill
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid
Alice T. Shaw
Alice T. Shaw Harvard University
David R. Gandara
David R. Gandara University of California, Davis
Shirish M. Gadgeel
Shirish M. Gadgeel University of Michigan–Ann Arbor
Ritsuko Komaki
Ritsuko Komaki The University of Texas MD Anderson Cancer Center
Vassiliki A. Papadimitrakopoulou
Vassiliki A. Papadimitrakopoulou The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine opens various alternative and supportive roles beyond the traditional MD route. Many students explore online pathways in nursing and healthcare due to their flexibility and affordability.

If you're drawn to advanced practice nursing, pursuing the cheapest np school online can lead to a Nurse Practitioner role, which is both in high demand and impactful. For those wanting to advance as leaders or educators in nursing, enrolling in one of the phd nursing education online programs can open doors to academic or research-oriented careers.

Registered Nurses (RNs) looking to expand their credentials can benefit from the cheapest rn to bsn online programs, which provide a cost-effective and flexible route to a Bachelor of Science in Nursing. Likewise, professionals seeking a master's degree can find value in the cheapest online msn programs, making graduate education more accessible.

Exploring these affordable and flexible online degrees can help aspiring healthcare professionals find the right fit for their goals and budgets while contributing meaningfully to the medical field.

Best Scientists Citing Corey J. Langer

Trending Scientists

Recently Published Articles